PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
0.00 - 0.01
0.00 - 0.02
1.30M / 496.9K (Avg.)
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-0.00%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-0.00%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
0.00%
EBIT growth below 50% of XRF.AX's 2.69%. Michael Burry would suspect deeper competitive or cost structure issues.
0.00%
Operating income growth under 50% of XRF.AX's 2.69%. Michael Burry would be concerned about deeper cost or sales issues.
0.00%
Net income growth under 50% of XRF.AX's 6.52%. Michael Burry would suspect the firm is falling well behind a key competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.33%
Share reduction more than 1.5x XRF.AX's 2.84%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-84.63%
Negative 10Y revenue/share CAGR while XRF.AX stands at 12.69%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-69.45%
Negative 5Y CAGR while XRF.AX stands at 10.96%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-57.15%
Negative 3Y CAGR while XRF.AX stands at 26.58%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
No Data
No Data available this quarter, please select a different quarter.
-115.67%
Negative 5Y OCF/share CAGR while XRF.AX is at 740.87%. Joel Greenblatt would question the firm’s operational model or cost structure.
-37.87%
Negative 3Y OCF/share CAGR while XRF.AX stands at 274.10%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-103.43%
Negative 10Y net income/share CAGR while XRF.AX is at 910.18%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-130.23%
Negative 5Y net income/share CAGR while XRF.AX is 198.61%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
63.17%
Below 50% of XRF.AX's 782.14%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.33%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
No Data
No Data available this quarter, please select a different quarter.
463.46%
R&D growth of 463.46% while XRF.AX is zero. Bruce Berkowitz checks if the moderate investment leads to meaningful product differentiation.
-0.00%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.